Affinity DataIC50: 2.10nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 20nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 24nMAssay Description:Antagonist activity at human delta opioid receptor expressed in HEK cells assessed as inhibition of SNC-80-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 172nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 204nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 212nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 222nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 250nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 260nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 286nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 338nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 340nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 347nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 419nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 451nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 462nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 596nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 610nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 660nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 680nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 680nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 721nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.00E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.30E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.30E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.40E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.49E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.50E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.60E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.60E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 1.73E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 1.83E+3nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.00E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 2.14E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 2.70E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Astrazeneca Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3.00E+3nMAssay Description:Inhibition of human ERG by electrophysiology assayMore data for this Ligand-Target Pair
Affinity DataIC50: 3.08E+3nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 3.50E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 3.94E+3nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 4.18E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 4.20E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 8.08E+3nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 8.19E+3nMAssay Description:Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 8.24E+3nMAssay Description:Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS bindingMore data for this Ligand-Target Pair